New at CADTH — June 2022

Corporate News and Events

1. Canada's Drug Agency Hosts a National Roundtable on Models of Care for Long COVID
   As a trusted partner and convenor of health system leaders, Canada's Drug Agency supported jurisdictional efforts to address post–COVID-19 condition by convening an invitational roundtable on June 1, 2022. Learn more.
    
2. Information Session — “What We Heard” Regarding the Proposed Framework for a Potential Pan-Canadian Formulary
   Join us on June 9, 2022, as Dr. Alexandra King and Mr. Allen Lefebvre, co-chairs of the Pan-Canadian Advisory Panel on a Framework for a Prescription Drug List, discuss highlights of the feedback heard from consultations on the development of a framework for a potential pan-Canadian prescription drug list (or formulary). Registration is required.

Canada's Drug Agency Reports and Recommendations

Reimbursement Reviews

Drug funding recommendations for Canada's federal, provincial, and territorial public drug programs. Reimbursement recommendations are based on comprehensive assessments of the clinical and pharmacoeconomic evidence, as well as input from pharmaceutical companies, clinicians, and patient groups.

• prasterone (Intrarosa) for postmenopausal vulvovaginal atrophy
• Alpha1-proteinase inhibitor (Human) (Zemaira) for Severe Alpha1-proteinase inhibitor deficiency
• selpercatinib (Retevmo) for RET fusion-positive non-small cell lung cancer
• Ripretinib (Qinlock) for gastrointestinal stromal tumours
• provisional funding algorithm for multiple myeloma

Canada's Drug Agency Horizon Scans

Information about new and emerging health technologies that could impact the delivery of care in Canada.

• An Overview of Continuous Learning Artificial Intelligence-Enabled Medical Devices – Emerging Health Technologies
• An Overview of New and Emerging Technologies for Early Diagnosis of Alzheimer Disease – Emerging Health Technologies

Canada's Drug Agency Health Technology Reviews

Independent assessments of health technologies. Assessments consist of 1, or a combination, of the following: an environmental scan, a rapid review, a clinical (or systematic) review, an economic review, and a review of patient perspectives. They may also include an assessment of the legal, ethical, social, implementation, environmental, and policy implications of the health technology. Recommendations on the appropriate use of health technologies are provided where applicable.

• Melatonin for the Treatment of Insomnia: A 2022 Update - Rapid Review
• Reconsolidation and Consolidation Therapies for the Treatment and Prevention of Post-Traumatic Stress Disorder – Rapid Review
• Robotic-Assisted Spinal Surgery – Rapid Review
• Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Following Retinal Detachment Surgery – Rapid Review
• Guidelines for Pediatric Immune Thrombocytopenia – Rapid Review
• Monitoring Patients With Psychotic Disorders for Clozapine-Induced Myocarditis or Cardiomyopathy – Rapid Review
• Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Refractory or High-Risk Patients – Rapid Review
• Melatonin for the Treatment or Prevention of Delirium – Rapid Review
• Clinical Effectiveness of Second-Generation Injectable Antipsychotics – Rapid Review
• Post‒COVID-19 Condition Scoping Review - Scoping
• Stepped Care Models for Chronic Pain – Technology Review
• Pre-Surgical Screening Tools and Risk Factors for Chronic Post-Surgical Pain – Technology Review
• PET-CT Exam Volumes: Comparison of Canada With Other Countries – CMII Report

Canada's Drug Agency Reference Lists

Lists of the publicly available and grey literature that identify the evidence and the gaps in the scientific literature.

• Opioid Agonist Therapies for Adults with Opioid Dependence in Correctional Settings
• Infliximab for Graft Versus Host Disease
• Physical Restraints for Adults With Mental Health Conditions or Dementia in Inpatient and Correctional Settings
• Behaviourally Based Interventions for Tobacco Smoking Prevention in Children and Adolescents
• Non-Pharmacological Interventions for Tobacco Smoking Cessation in Children and Adolescents
• Therapeutic Glasses for People With Vision Problems Following Concussion
• Metformin Extended Release versus Immediate Release for Type 2 Diabetes
• Labiaplasty for Adults With Labia Minora Hypertrophy
• Use of Insulin Pumps in Adults and Older Adults Living With Type 1 or Type 2 Diabetes
• Abdominal Aortic Aneurysm Screening for Asymptomatic Adults

Other Canada's Drug Agency Tools

• Hospital News article: Thinking beyond medications for chronic pain management
• In Brief:
  • Post‒COVID-19 Condition Scoping Review
  • Intraocular Lenses for Infants with Aphakia
• Pre-Surgical Screening Tools and Risk Factors for Chronic Post-Surgical Pain: A Summary
• New Evidence Bundle: Evidence on Post–COVID-19 Condition

Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please contact your Canada's Drug Agency Liaison Officer.

Canada's Drug Agency E-Alerts: Subscribe to receive the latest Canada's Drug Agency news, reports, feedback opportunities, and events.